What is the recommended dosing regimen for the Climara transdermal estradiol patch (including progesterone supplementation) in a woman with an intact uterus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Climara Dosing for Women with Intact Uterus

For a woman with an intact uterus, Climara (transdermal estradiol) should be dosed at 50-100 μg/day patches applied twice weekly, with mandatory addition of a progestogen to prevent endometrial hyperplasia—either as a combined patch (estradiol/levonorgestrel) or by adding oral micronized progesterone 200 mg daily for 12-14 days per month (sequential) or 100 mg daily continuously. 1

Estradiol Dosing

The FDA-approved Climara Pro combined patch delivers 0.045 mg (45 μg) estradiol plus 0.015 mg levonorgestrel daily, applied weekly on the lower abdomen 1. However, guidelines suggest physiologic estradiol levels are typically achieved with 100 μg transdermal patches in most women with premature ovarian insufficiency 2, though standard menopausal dosing often uses 50 μg patches 3.

Application Protocol:

  • Apply to smooth, clean, dry skin on lower abdomen (not breasts or waistline)
  • Change patch twice weekly for most formulations, or weekly for specific brands
  • Rotate application sites with at least 1 week between same site 1
  • Continuous application without breaks (not cyclical) 3

Mandatory Progestogen Supplementation

Critical caveat: Women with an intact uterus absolutely require progestogen to prevent endometrial hyperplasia and cancer 4. You have two evidence-based options:

Option 1: Combined Transdermal Patch (Preferred for Compliance)

  • Sequential regimen: Estradiol patches alone for 2 weeks, then combined estradiol/levonorgestrel patches (50 μg estradiol + 10 μg levonorgestrel) for 2 weeks; repeat without interruption 3
  • Continuous regimen: Combined patches (50 μg estradiol + 7 μg levonorgestrel) continuously to avoid withdrawal bleeding 3

Option 2: Separate Progestogen Supplementation

If combined patches unavailable, add oral progestogen to continuous transdermal estradiol:

First-line progestogen choices 4, 3:

  • Micronized progesterone: 200 mg daily for 12-14 days per month (sequential), OR 100 mg daily continuously
  • Medroxyprogesterone acetate (MPA): 10 mg daily for 12-14 days per month (sequential), OR 2.5 mg daily continuously
  • Norethindrone acetate: 5 mg for 10-12 days per month (sequential), OR 0.35 mg daily continuously

Micronized progesterone is preferred due to its physiological profile and safety, particularly regarding cardiovascular and breast cancer risk 3.

Dosing Algorithm by Clinical Context

Standard Menopausal Women:

  • Start with 50 μg estradiol patches twice weekly
  • Add progestogen as above
  • May increase to 100 μg if symptoms persist 2

Premature Ovarian Insufficiency (POI):

  • Often require 100 μg estradiol patches to achieve physiologic levels 2
  • Continue until age 51 (natural menopause age) 2

Special Populations (Cancer Survivors, Cardiovascular Risk):

  • Transdermal route strongly preferred over oral due to avoidance of first-pass hepatic metabolism, reducing thromboembolism risk 3
  • Use 50-100 μg patches as above

Key Clinical Pitfalls

  1. Never use estrogen alone in women with intact uterus—this dramatically increases endometrial cancer risk 1

  2. Transdermal superior to oral for women with VTE risk, hypertension, hypertriglyceridemia, obesity, diabetes, or gallbladder disease due to avoidance of hepatic first-pass effects 5

  3. Sequential vs continuous progestogen: Sequential regimens (12-14 days/month) cause withdrawal bleeding but may be preferred initially; continuous regimens avoid bleeding but may cause irregular spotting initially 3

  4. Monitor for undiagnosed vaginal bleeding—requires endometrial sampling before initiating therapy 1

  5. Patch adhesion issues: If patch falls off, may reapply same patch to different site or apply new patch and continue original schedule. Only one patch at a time 1

  6. Avoid sun exposure to patch site for prolonged periods 1

Treatment Duration

Use the lowest effective dose for shortest duration consistent with treatment goals, with re-evaluation every 3-6 months 1. For POI specifically, continue at least until age 51 years 2.

References

4
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

5
Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

Should I begin vaginal estradiol cream now and delay progesterone until a transdermal estrogen patch becomes available?
What are the available strengths of the estradiol transdermal patch?
What are the recommended dosages and dosing schedule for the Climara (estradiol) transdermal patch, and how should it be titrated for post‑menopausal women?
What estradiol patch dose and oral progesterone regimen are equivalent for transitioning a 50‑year‑old perimenopausal woman who currently applies a daily cream containing 5.25 mg estradiol and 112.5 mg progesterone?
What is the differential diagnosis, appropriate work‑up, and management for a 22‑year‑old woman with markedly low progesterone (<0.5 ng/mL) and low estradiol (<30 pg/mL)?
What is pituitary apoplexy?
In a patient colonised with methicillin‑resistant Staphylococcus aureus (MRSA) undergoing functional endoscopic sinus surgery (FESS), what pre‑operative decolonisation and peri‑operative antibiotic prophylaxis should be used?
What bolus intravenous proton‑pump inhibitor should be given for an acute upper gastrointestinal bleed?
Does transdermal progesterone cream provide a calming (anxiolytic) effect, or is this effect only achieved with oral micronized progesterone?
In a patient previously treated for Fusobacterium nucleatum with oral cefdinir and metronidazole (and inpatient ceftriaxone plus metronidazole), who is now rehospitalized and the hospital lacks cefdinir, what oral antibiotic can replace cefdinir to provide coverage for Fusobacterium nucleatum?
What are the advantages of using a fentanyl IV bolus versus dexmedetomidine (Precedex) for sedation in brief non‑intubated adult procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.